Biogen
BIIB
1,010 hedge funds and large institutions have $37.9B invested in Biogen in 2019 Q2 according to their latest regulatory filings, with 84 funds opening new positions, 315 increasing their positions, 452 reducing their positions, and 143 closing their positions.
4.2% less ownership
Funds ownership: 87.69% → 83.49% (-4.2%)
7% less funds holding
Funds holding: 1,085 → 1,010 (-75)
7% less capital invested
Capital invested by funds: $40.8B → $37.9B (-$2.9B)
27% less call options, than puts
Call options by funds: $883M | Put options by funds: $1.2B
27% less funds holding in top 10
Funds holding in top 10: 22 → 16 (-6)
30% less repeat investments, than reductions
Existing positions increased: 315 | Existing positions reduced: 452
41% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 143
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$352M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$254M |
| 3 |
Renaissance Technologies
New York
|
+$197M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$180M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$149M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$534M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$326M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$216M |
| 4 |
JP Morgan Chase
New York
|
-$191M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$191M |
BIIB Hedge Fund Activity: Q2 2019 in Review
1,010 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2019, worth a combined $37.9B — down 7.1% from $40.8B a quarter earlier.
Sellers outnumbered buyers: 143 funds closed out of BIIB and 84 opened new positions — a net loss of 59 holders — while 452 trimmed existing stakes and 315 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $352M. The largest seller was ClearBridge Investments, cutting an estimated $534M.
- 1,010 institutional investors held Biogen (BIIB) as of Q2 2019, down from 1,085 in Q1 2019.
- Funds reported $37.9B of Biogen stock for Q2 2019, down 7.1% quarter-over-quarter.
- 84 funds opened new Biogen positions in Q2 2019 and 143 closed out, a net change of -59 holders.
- The largest Biogen buyer in Q2 2019 was D.E. Shaw & Co, an estimated $352M added.
- The largest Biogen seller in Q2 2019 was ClearBridge Investments, an estimated $534M sold.
Based on aggregated 13F filings for Q2 2019.